Physician profile
Daniel S Blumer
NPI 1598707770
$10,916.40
in general payments reported to CMS, 2019-2025
35 companies · $1,418 in 2025
The $1,418 reported for 2025 was more than what 91% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,062 · 2020: $1,503 · 2021: $2,142 · 2022: $1,953 · 2023: $1,225 · 2024: $1,613 · 2025: $1,418.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,256.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,255.66 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $2,462.93 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,184.77 | 2019-2025 | Jardiance, Tradjenta, Spiriva Respimat |
| Pfizer INC. | $1,073.17 | 2019-2025 | |
| Novo Nordisk INC | $1,050.57 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $947.08 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $906.30 | 2019-2025 | Vraylar, Creon, Linzess |
| Lilly USA, LLC | $695.44 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $390.31 | 2019-2022 | |
| Astellas Pharma US INC | $287.53 | 2020-2025 | Veozah |
| Janssen Pharmaceuticals, INC | $229.04 | 2019-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $204.24 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $167.99 | 2019-2023 | |
| Merck Sharp & Dohme LLC | $155.85 | 2019-2024 | Gardasil 9, Capvaxive, Gardasil |
| Biohaven Pharmaceuticals, INC. | $153.89 | 2021 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $139.49 | 2022 |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $107.42 | 2024-2025 | Repatha, Krystexxa |
| Kowa Pharmaceuticals America, INC. | $100.40 | 2022-2025 | Zoryve, Seglentis |
| Verona Pharma, INC. | $90.28 | 2025 | Ohtuvayre |
| Xeris Pharmaceuticals, INC. | $70.24 | 2022-2025 | Gvoke Hypopen |
| Allergan, INC. | $68.62 | 2019-2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $56.57 | 2020-2023 | Xifaxan |
| Bayer Healthcare Pharmaceuticals INC. | $55.68 | 2024-2025 | |
| Sumitomo Pharma America, INC. | $52.71 | 2024 | Gemtesa |
| E.R. Squibb & Sons, L.L.C. | $42.15 | 2019-2022 | |
| Amneal Pharmaceuticals LLC | $34.12 | 2022 | |
| Novartis Pharmaceuticals Corporation | $33.14 | 2023 | |
| Exact Sciences Corporation | $24.63 | 2024 | Cologuard Collection Kit |
| Intersect Ent, INC. | $22.24 | 2020 | |
| Almatica Pharma LLC | $19.13 | 2021 | |
| Grifols USA, LLC | $18.40 | 2022 | |
| Phathom Pharmaceuticals, INC. | $16.64 | 2024 | Voquezna |
| Abbott Laboratories | $15.46 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.32 | 2023 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $13.86 | 2021 | |
| Evoke Pharma, INC. | $11.79 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daniel Blumer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.